Please assess the completion status of the following clinical trial:

Trial Title: Ph II Concurrent Chemo t/Docetaxel/Carboplatin/Radio Therapy-consolidation t/Locally Adv Inoperable Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must voluntarily sign and date an informed consent before the initiation of any study procedures~* Patients must have non-metastatic, inoperable, Stage IIIA or IIIB histologically or cytologically documented NSCLC without evidence of malignant pleural effusion~* Patients must not have received any prior systemic chemotherapy, thoracic radiotherapy or surgical resection for treatment of NSCLC~* Patients must have at least one site of unidirectionally measurable disease~* Patients must be ≥ 3 weeks from a formal exploratory thoracotomy~* Patients must have a Radiation Oncology and Medical Oncology consult and approval prior to study entry~* Patients must be ≥ 18 years of age~* Women of childbearing potential must have a negative baseline serum pregnancy within 7 days prior to Week 1, Day 1 and must not be breast feeding.~* Women of childbearing potential and men with a sexual partner of child bearing potential must use an effective method of contraception beginning prior to study entry, for the duration of the study participation and for a minimum of 3 months after the last dose of chemotherapy.~* Patients must have adequate hepatic, renal, lung and bone marrow function as defined below:~  * Absolute neutrophil count (ANC) \> 1,500/mm3~ * Hemoglobin \> 9.0 gm/dL~ * Creatinine \< 1.5~ * Platelets \> 100,000/mm3~ * Total bilirubin within normal limits (WNL)~ * AST or ALT and Alkaline Phosphatase must be within the range allowing for eligibility, as per chart on page 10 of the protocol.~* Calculated CrCl \> 50 ml/min (via Cockroft-Gault formula).~* Forced expiratory volume in 1 second (FEV 1) \> 800 ml~Exclusion Criteria:~* Known hypersensitivity to drugs formulated with polysorbate 80~* Peripheral neuropathy Grade ≥ 2.~* Wet stage IIIB (documented malignant pleural effusion) or stage IV NSCLC~* Previous chemotherapy or radiation therapy~* Any concomitant malignancy, brain metastasis or uncontrolled, clinically significant medical or psychiatric disorder~* Pregnant or nursing women~* A greater than or equal to 10% weight loss over the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Therapeutic Intervention (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).